How many drugs treat Neonatal pneumonia?

Drug Landscape tracks 9 marketed treatments for Neonatal pneumonia (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/neonatal-pneumonia.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Neonatal pneumonia — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Neonatal pneumonia (disease) competitive landscape: 9 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

9 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Neonatal pneumonia, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Arikayce Kit	AMIKACIN	Bristol-Myers Squibb	Aminoglycoside Antibacterial		1981-01-01
Claforan	CEFOTAXIME	Sterimax	Cephalosporin Antibacterial		1981-01-01
Gentamicin	Gentamicin Sulfate	Merck & Co.	gentamicin	Dihydrofolate reductase	1970-01-01
Garamycin	GENTAMICIN	Merck & Co.	Aminoglycoside Antibacterial	Transient receptor potential cation channel subfamily V member 5	1970-01-01
Benzamycin	Erythromycin Lactobionate	Pfizer	Macrolide	Potassium voltage-gated channel subfamily H member 2	1964-01-01
E-Mycin	erythromycin	Generic (originally Abbott/Lilly)	Macrolide [EPC]	Aldehyde oxidase, Bile salt export pump, Cytochrome P450 1B1	1952-01-01
Penicillin G Potassium In Plastic Container	Benzylpenicillin	Pfizer	Penicillin-class Antibacterial		1947-01-01
Vancocin	vancomycin	ANI Pharmaceuticals		Alpha-2A adrenergic receptor, D-alanyl-D-alanine dipeptidase, UDP-N-acetylglucosamine--N-acetylmuramyl-(pentapeptide) pyrophosphoryl-undecaprenol N-acetylglucosamine transferase
penicillin	penicillin	Karlstad University		Bacterial penicillin-binding protein, Beta-lactamase, Beta-lactamase TEM

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Pfizer · 2 drugs in Neonatal pneumonia
Merck & Co. · 2 drugs in Neonatal pneumonia
Bristol-Myers Squibb · 1 drug in Neonatal pneumonia
Generic (originally Abbott/Lilly) · 1 drug in Neonatal pneumonia
Karlstad University · 1 drug in Neonatal pneumonia
· 1 drug in Neonatal pneumonia
Sterimax · 1 drug in Neonatal pneumonia
ANI Pharmaceuticals · 1 drug in Neonatal pneumonia

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Neonatal pneumonia:

Cite this brief

Drug Landscape (2026). Neonatal pneumonia — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/neonatal-pneumonia. Accessed 2026-06-10.

Neonatal pneumonia full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing